Transfusion-associated graft versus host disease (TAGVHD)

Ready to upload
Record number: 
Adverse Occurrence type: 
MPHO Type: 
Estimated frequency: 
Case report. Patient with systemic lupus erythematosus treated with fludarabine.
Time to detection: 
10 days
Alerting signals, symptoms, evidence of occurrence: 
Fever, skin rash, pancytopenia, increased bilirubin, abnormal liver function tests.
Demonstration of imputability or root cause: 
Marrow biopsy showed severe aplasia and skin biopsy was consistent with GVHD. Allele-level HLA typing on circulating lymphocytes revealed extra HLA alleles not present in patient's pretreatment sample, but identical to the HLA haplotypes of an unrelated platelet donor. Non-leukocyte reduced, non-irradiated platelet from donor who was a previous platelet transfusion donor (90 days previously).
Imputability grade: 
3 Definite/Certain/Proven
Groups audience: 
Suggest new keywords: 
Non-leukocyte reduced
Reference attachment: 
Suggest references: 
Leitman S.F., Tisdale, J.F., Bolan, C.D., Popovshky, M.A., Liippel, J.H., Balow, J.E., Boumpas, D.T. and Illei, G.G. (2003). Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 43(12):1667-71.